BBIO
BridgeBio Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$74.21
−1.59%Year over year
Reported trailing growth
- Revenue
- +193.4%
- EBITDA
- +6.3%
- EBIT
- +17.2%
- EPS
- +12.5%
- Free cash flow
- +11.3%
- Operating cash flow
- +10.6%
Forward estimates
Based on analyst estimates
- Revenue
- +86.4%
- EBITDA
- +77.6%
- EPS
- +59.1%
Three-year CAGR
- Revenue
- +86.3%
- EBITDA
- -54.0%
- EBIT
- +4.0%
- Net income
- -36.1%
- EPS
- -31.6%
- Free cash flow
- +14.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026